Tag Archives: semaglutide

GLP-1 receptor agonists have transformed type 2 diabetes care. Yet for many patients, gastrointestinal side effects from GLP-1 therapy, such as nausea, vomiting, and constipation, can threaten long-term adherence. Have you ever had a patient achieve an impressive A1C reduction but consider stopping therapy because of persistent nausea? You are …

As more patients succeed on GLP-1 therapy, conversations about tapering these medications are becoming increasingly common in metabolic care. When patients reach meaningful goals in weight reduction, A1C improvement, or cardiometabolic risk, clinicians naturally begin asking what comes next. Is it safe to stop treatment? More importantly, can progress be …

Patients taking GLP-1 receptor agonists often describe a surprising change: the “volume” of food thoughts seems to turn down. This experience, often described as a reduction in food noise with GLP-1 therapy, reflects measurable neuroendocrine shifts in appetite regulation and reward signaling. For clinicians, understanding and explaining this phenomenon is …

For years, GLP-1 receptor agonists have been associated with older adults who already have type 2 diabetes or established cardiovascular disease. However, metabolic dysfunction does not suddenly appear at age 60. In fact, obesity, insulin resistance, and prediabetes often begin decades earlier. That is why conversations around GLP-1 therapy in …

GLP-1 receptor agonists have changed diabetes care faster than almost any therapy in recent history. In many ways, one medication now touches glucose control, weight loss, cardiovascular risk, and even liver health. However, while outcomes have evolved, the typical clinic visit has stayed the same. As a result, clinicians often …

The scale is moving fast, clothes are fitting better, and blood sugar numbers are improving. For many people using GLP-1 medications, weight loss can feel almost effortless at first. Yet beneath those encouraging changes, another question often emerges: is muscle being lost along with fat? For individuals focused on long-term …

What happens when a medication that quietly supports weight loss and glucose control suddenly disappears? For many patients, an unexpected break in GLP-1 therapy feels like pulling the rug out from under hard-earned progress. Supply shortages, insurance denials, side effects, or planned drug holidays are now common reasons people stop …

GLP-1–based therapies have quickly become a cornerstone of modern diabetes care. While most clinicians think of these agents for glucose lowering and weight loss, growing evidence suggests they may also support better blood pressure control. For patients living with diabetes and hypertension, that overlap raises an important question. Can GLP-1 …

Glucagon‑like peptide‑1 receptor agonists (GLP‑1 RAs) have transformed type 2 diabetes management by improving blood sugar control and promoting weight loss. Yet as clinical use grows, so does interest in how GLP‑1 medications affect skeletal health — particularly their impact on bone density, remodeling, and fracture risk. This article unpacks …

Asthma is a chronic inflammatory disease of the airways that affects millions worldwide and often overlaps with metabolic conditions such as obesity and type 2 diabetes. Recently, interest has grown in whether glucagon‑like peptide‑1 receptor agonists (GLP‑1 RAs)—a class of drugs commonly used to manage diabetes and obesity—could help reduce …